Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mavrostobart + gemcitabine
- Development stage
- Unknown
- Lead developer
- Phanes Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Mavrostobart + gemcitabine is a combination therapy consisting of mavrostobart (PT199), a humanized monoclonal antibody targeting the ecto-5'-nucleotidase (CD73) enzyme, and gemcitabine, a nucleoside analog chemotherapy. Mavrostobart inhibits the conversion of adenosine monophosphate (AMP) to immunosuppressive adenosine in the tumor microenvironment, thereby enhancing anti-tumor immune responses and potentially overcoming resistance to checkpoint inhibitors. Gemcitabine acts as a cytotoxic agent by inhibiting DNA synthesis through incorporation into DNA and inhibition of ribonucleotide reductase. This combination is being developed by Phanes Therapeutics and is currently being evaluated in the Phase 1/2 MORNINGSTAR clinical trial for the treatment of advanced solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), often in combination with nab-paclitaxel.
- Other names
- PT199 + gemcitabine
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on mavrostobart + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mavrostobart + gemcitabine.